Satellite Symposium Advanced Accelerator Applications, A Novartis Company Friday, October 30, 13:50-15:20 Channel 4 Session Title Evolution of theragnostics and targeted therapies for advanced prostate cancer: the role of the multidisciplinary team Objectives:

• Explore the treatment landscape and unmet need in advanced prostate cancer • Discuss the new targeted treatment options in development for advanced prostate

cancer, including radioligand therapy, poly-ADP ribose polymerase inhibitors (PARPi), and other targeted modalities

• Review the role of the nuclear medicine physician in the management of advanced prostate cancer patients

• Discuss the importance of MDT collaboration to achieve the best outcomes for advanced prostate cancer patients

Chairperson: Prof. Joe O’Sullivan Speakers: Prof. Bertrand Tombal Dr. Daniel Heinrich Prof. Dr. med. Ken Herrmann

Lecture time: 5 min Welcome and introduction

Chair: Prof. Joe O’Sullivan

Lecture time: 20 min Current treatments and unmet needs in advanced

prostate cancer

Speaker: Prof. Bertrand Tombal

Lecture time: 20 min

Advanced targeted therapies on the radar

Speaker: Prof. Joe O’Sullivan

Lecture time: 20 min

Role of the nuclear medicine physician in the management of advanced prostate cancer patients

Speaker: Prof. Dr. med. Ken Herrmann

Lecture time: 15 min Case study: The role of the MDT in treatment

decisions and patient follow-up

Speaker: Dr. Daniel Heinrich

Lecture time: 10 min

Panel discussion

Chair: Prof. Joe O’Sullivan Panel: Prof. Bertrand Tombal, Dr. Daniel Heinrich, and Prof. Dr. med. Ken Herrmann